Principal Financial Group Inc Maxcyte, Inc. Transaction History

Principal Financial Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$3.63 - $5.0 $42,325 - $58,300	-11,660 Reduced 44.19%	14,724 $57,000
Q1 2024 Apr 29, 2024	SELL	$3.94 - $5.38 $8,100 - $11,061	-2,056 Reduced 7.23%	26,384 $110,000
Q4 2023 Feb 07, 2024	SELL	$2.6 - $5.24 $5,311 - $10,705	-2,043 Reduced 6.7%	28,440 $133,000
Q3 2023 Nov 02, 2023	BUY	$3.02 - $5.1 $8,395 - $14,177	2,780 Added 10.04%	30,483 $95,000
Q2 2023 Aug 07, 2023	BUY	$3.69 - $5.35 $6,487 - $9,405	1,758 Added 6.78%	27,703 $127,000
Q1 2023 May 09, 2023	BUY	$4.03 - $5.89 $13,536 - $19,784	3,359 Added 14.87%	25,945 $128,000
Q4 2022 Feb 09, 2023	BUY	$4.92 - $7.4 $111,123 - $167,136	22,586 New	22,586 $123,000
Q2 2022 Aug 10, 2022	SELL	$3.59 - $6.81 $49,373 - $93,657	-13,753 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$5.26 - $10.84 $4,092 - $8,433	778 Added 6.0%	13,753 $96,000
Q4 2021 Feb 09, 2022	BUY	$8.87 - $12.94 $115,088 - $167,896	12,975 New	12,975 $132,000

124

65.6M

Ticker MXCT
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 101,724,000
Market Cap $426M
Description
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.